HEL · ORNBV.HE
Orion Oyj
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
Loading market information…
HEL · REG1V.HE · EUR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Revenio Group Oyj’s quoted price sits in the lower half of its reported 52-week range, 58.15% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Revenio Group Oyj’s forward annual dividend is €0.40 per share, paid annual. The forward yield is 3.85% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Revenio Group Oyj’s next earnings report is currently expected on Nov 12, 2026, with estimated earnings per share of €0.09. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Revenio Group Oyj’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:51 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 | Apr 29, 2025 | €0.16-5.88% vs estimate | €26.10M-6.34% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | €0.25-3.85% vs estimate | €30.50M-1.1% vs estimate |
|---|
| Q3 2024 | Oct 31, 2024 | €0.16-23.81% vs estimate | €23.90M-22.5% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€100.00+€1.60 (+1.63%)
Orion Oyj’s quoted price sits in the upper half of its reported 52-week range, 0.5% below the high.
€6.04+€0.03 (+0.5%)
Terveystalo Oyj’s quoted price sits in the lower half of its reported 52-week range, 42.03% below the high.
€8.43-€0.16 (-1.86%)
Pihlajalinna Oyj’s quoted price sits in the lower half of its reported 52-week range, 45.44% below the high.
£0.32£0.00 (0.0%)
Faron Pharmaceuticals Oy’s quoted price sits in the lower half of its reported 52-week range, 85.0% below the high.
€8.80-€0.07 (-0.79%)
Nexstim Plc’s quoted price sits in the lower half of its reported 52-week range, 42.67% below the high.
€0.80+€0.15 (+22.48%)
Nanoform Finland Oyj’s quoted price sits in the lower half of its reported 52-week range, 34.98% below the high.
€1.01-€0.01 (-0.99%)
Modulight Oyj’s quoted price sits in the lower half of its reported 52-week range, 27.17% below the high.
€1.41+€0.04 (+3.07%)
Optomed Oyj’s quoted price sits in the lower half of its reported 52-week range, 67.44% below the high.
